For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) inhibitor use is associated with a reducti ...

Some of these peptide medications include glucagon-like peptide-1 (GLP-1) receptor agonists. They also include a combination of GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Digital health companies faced high advertising costs and focused on returns on investments in the third quarter.

Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists could avert 42,000 deaths annually ...

Weight loss can be a challenge, even for those who eat healthily and exercise regularly. But injectable type 2 diabetes ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

The following is a summary of “Sodium-glucose cotransporter 2 inhibitors and glaucoma in patients with type 2 diabetes,” ...

A s doctors and researchers learn more about Ozempic's health benefits, many are impressed. Besides lowering blood sugar in ...

A new nationwide study led by investigators from Cedars-Sinai and other institutions reveals a significant rise in ...

Once-weekly semaglutide shows significant reduction in knee osteoarthritis pain and body weight in adults with obesity, a ...